Skip to main content
. Author manuscript; available in PMC: 2022 Mar 2.
Published in final edited form as: Prog Neuropsychopharmacol Biol Psychiatry. 2020 Sep 6;106:110096. doi: 10.1016/j.pnpbp.2020.110096

Table 2.

Peripheral blood mononuclear cell endocannabinoids in psychotic disorders.

Condition & treatment n (cases/controls) Cell type Receptors Metabolic enzymes Greater symptom severity Reference
1CB1 1CB2 1Anandamide 12-AG
Mixed (treated & untreated)
   First-episode psychosis 95/90 PBMC - n.s. ↓NAPE -PLD ↓DAGL ↓FAAH Bioque et al., 2013
↑FAAH ↑MAGL
 Cannabis+ 46/71 ↓CB2 ↓NAPE-PLD ↓DAGL
 Cannabis− 49/71 n.s. n.s. ↓DAGL
Untreated
 Schizophrenia 35/35 PBMC ↑mRNA ↑mRNA - - ↑CB1 Chase et al., 2016
↑CB2
Treated
 Schizophrenia 162/94 PBMC ↑mRNA - - - - Moretti et al., 2018
 Schizophrenia 25/34 PBMC ↑mRNA n.s.NAPE-PLD n.s. DAGL - D’Addario et al., 2017
n.s. n.s. FAAH n.s. MAGL
mRNA mRNA mRNA
 Schizophrenia 55/48 Neutrophils ↑CB1 ↑CB2 - - - de Campos-Carli et al., 2017
Monocytes ↑CB1 ↑CB2 - -
NK-cells n.s. ↑CB2 - -
B-cells ↓CB1 ↓CB2 - -
T cells CD8+ n.s. n.s. - -
T cells CD4+ ↑CB1 n.s. - -
 Schizophrenia 53/22 Monocytes n.s. n.s. - - Ferretjans et al., 2014
NK-cells n.s. n.s. - - n.s.
B-cells n.s. n.s. - -
T cells CD8+ n.s. n.s. - -
T cells CD4+ n.s. n.s. - -

↑: higher; ↓: lower; n.s.: no significant difference from healthy controls; -: no available data;

Cannabis+: patients that met criteria for cannabis abuse or dependence;

Cannabis−: patients that did not meet criteria for cannabis abuse or dependence;

PBMC: Peripheral Blood Mononuclear Cells; 2-AG: 2-arachidonoyglycerol; NK-Cells: Natural Killer cells; NAPE-PLD: N-acyl Phosphatidylethanolamine Phospholipase D; FAAH: Fatty Acid Amide Hydrolase; DAGL: Diacylglycerol Lipase; MAGL: Monoacylglycerol Lipase;

1

Note: result refers to protein levels unless otherwise indicated.